Fortis Group Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 65.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 872 shares of the company's stock after selling 1,658 shares during the quarter. Fortis Group Advisors LLC's holdings in Johnson & Johnson were worth $145,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Easterly Investment Partners LLC increased its stake in Johnson & Johnson by 27.5% during the first quarter. Easterly Investment Partners LLC now owns 117,025 shares of the company's stock worth $19,407,000 after acquiring an additional 25,211 shares during the last quarter. Kooman & Associates purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $317,000. Members Trust Co boosted its position in shares of Johnson & Johnson by 13.2% in the first quarter. Members Trust Co now owns 8,658 shares of the company's stock worth $1,436,000 after buying an additional 1,009 shares during the period. Frederick Financial Consultants LLC boosted its position in shares of Johnson & Johnson by 3.8% in the first quarter. Frederick Financial Consultants LLC now owns 2,233 shares of the company's stock worth $370,000 after buying an additional 82 shares during the period. Finally, Bailard Inc. boosted its position in shares of Johnson & Johnson by 4.5% in the first quarter. Bailard Inc. now owns 141,294 shares of the company's stock worth $23,432,000 after buying an additional 6,087 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock traded up $0.67 on Friday, reaching $163.65. 9,764,459 shares of the company were exchanged, compared to its average volume of 8,138,164. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company's 50-day moving average is $154.10 and its two-hundred day moving average is $154.84. The firm has a market cap of $393.75 billion, a price-to-earnings ratio of 17.50, a P/E/G ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on JNJ shares. Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.11.
Read Our Latest Report on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
